Evidence- based Medicine Literature Review Jauch Symposium, May 2014.

Slides:



Advertisements
Similar presentations
Health Promotion in Primary Care
Advertisements

August 30, 2009 at CET. Ticagrelor compared with clopidogrel in patients with acute coronary syndromes – the PLATO trial.
3/28/2017© 2009, American Heart Association. All rights reserved.
Unstable angina and NSTEMI
Leadership. Knowledge. Community. Antiplatelet Therapy for the Primary Prevention of Vascular Events Working Group: Alan D. Bell, MD, CCFP and James D.
Summary Prepared by Melvyn Rubenfire, MD
Niacin Use in Patients with Low HDL-Cholesterol Receiving Intensive Statin Therapy William E. Boden, MD, FACC, FAHA Jeffrey Probstfield, MD, FACC, FAHA.
OmniHeart Feeding Study Presented at The American Heart Association Scientific Session 2005 Presented by Dr. Lawrence J. Appel OmniHeart Feeding Study.
Addressing Obesity and Exercise in Primary Care GSP 4 th Year Elective 2010.
Feb 25, 2013 (Epub ahead of print. Food industry: only food items Provision of Olive oil ~2 000 l/wk Provision of nuts 30 kg/wk walnuts 15 kg/wk almonds.
1 GRASP-AF Audit - Intro 8 th July 2010 Mark Gregory.
ROCKET-AF Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial.
Family Medicine Potpourri Some of the topics selected by editors of Journal Watch as top stories of 2013.
PROCESS vs. WA State SCS Study A Comparison of Study Design, Patient Population, and Outcomes August 29,2007.
Pexelizumab for the Reduction of Infarction and Mortality in Coronary Artery Bypass Graft ll (PRIMO-CABG II) Trial Presented at The American College of.
Where is the evidence? PHRM2010
ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial The telmisartan trial in cardiovascular protection Sponsored by Boehringer.
Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk.
Lipid Management in 2015: Risk & Controversies
Monotherapy using 6-MP or azathioprine for Crohn’s disease is dead: out with the old and in with the new Stephen B. Hanauer, MD Professor of Medicine Clinical.
Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.
The Research Question Alka M. Kanaya, MD Associate Professor of Medicine, Epidemiology & Biostatistics UCSF October 3, 2011.
1 Novel Oral Anticoagulants: Benefits and risks Matthew Moles, MD December 4, 2012 University of Colorado.
Update on Anti-platelets Gabriel A. Vidal, MD Vascular Neurology Ochsner Medical Center October 14 th, 2009.
Canadian Diabetes Association Clinical Practice Guidelines Acute Coronary Syndromes and Diabetes Chapter 26 Jean-Claude Tardif, Phillipe L. L’Allier, David.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel.
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
Evidence-based Medicine Journal Club Khalid Bin Abdulrahman Director of Medical Education Center King Saud University.
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
Vitamins - what is the evidence? Rohan Subasinghe.
Evidence Based Medicine Searching for Evidence. Evidence Based Practice: Steps 1.A sk focused clinical question 2.S earch for the best evidence 3.A ppraise/assess.
Jonathan A. Edlow, MD, FACEP Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cerebral.
Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.
Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Ramón Estruch, M.D., Ph.D., …and 18 others for PREDIMED study investigators Published:
Antiplatelet or Anticoagulant: Do They Have the same Efficacy? University of Central Florida Deborah Andrews RN, BSN.
Revealing the Mysteries of Information Mastery Steven R. Brown, MD Banner Good Samaritan Family Medicine Residency December 2010.
C.R.E.D.O. C lopidogrel for the R eduction of E vents D uring O bservation Multicenter Multinational (USA, Canada) Prospective Randomized Double Blind.
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
ARMYDA-4 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study Prospective, multicenter, randomized, double blind trial investigating.
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
Session 1 Review. 1. Which is the last of the four steps in the EBM process? Apply evidence to your patient Evaluate evidence for validity Formulate a.
HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.
The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial ONTARGET.
Evaluating the Medical Evidence ​ A TOOLKIT FOR THE INTERPRETING THE EFFECTIVENESS OF INTERVENTIONS Niteesh Choudhy, M.D., Ph.D.
Sifting through the evidence Sarah Fradsham. Types of Evidence Primary Literature Observational studies Case Report Case Series Case Control Study Cohort.
A Review of – Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Ted Williams Pharm D Candidate Monday Lab.
Journal Club 25 March 2015 Once daily amoxicillin vs Twice daily penicillin in GABHS pharyngitis ADC Feb 2008.
C-1 Efficacy of the Combination: Meta-Analyses Donald A. Berry, Ph.D. Frank T. McGraw Memorial Chair of Cancer Research University of Texas M.D. Anderson.
Applying CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage 2) in a Pre- Hospital Wilderness Context Paul B. Jones PGY1.
FRagmin® and Fast Revascularization during InStablity in Coronary artery disease FRISC II.
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Rikki Weems, PGY III August 20, 2015
Six Months vs Extended Oral Anticoagulation After a First Episode of Pulmonary Embolism ‘ The PADIS-PE Trial’ Nate Peyton.
The Use of Aspirin for Primary Prevention of Cardiovascular Diseases
Angela Aziz Donnelly April 5, 2016
Using evidence for patient care
HOPE: Heart Outcomes Prevention Evaluation study
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.
Antiplatelet Therapy and Secondary Prevention
NOACS: Emerging data in ACS/IHD
CV Risk Doesn't End in the Cath Lab
CV Risk Doesn't End in the Cath Lab
ARISE Trial Aggressive Reduction of Inflammation Stops Events
Omega-3s vs Pure EPA in Clinical Practice
Simvastatin in Patients With Prior Cerebrovascular Disease: HPS
Section C: Clinical trial update: Oral antiplatelet therapy
Presentation transcript:

Evidence- based Medicine Literature Review Jauch Symposium, May 2014

EBM – Key Concepts POEMS - Patient Oriented Evidence that Matters - changes our practice Strategies to keep up - 50,000 RCTs by 2019 Evaluating articles in context

Evidenced-based Sources Dynamed Essential Evidence Plus Cochrane Database ACP Journal Club US Preventive task force Trip database Some specialty guidelines

Oxford Centre Evidence Levels 1A- Systematic reviews 1B - Randomized controlled trials 2 - Cohort studies 3 - Case-control 4 - Case series 5 - Expert Opinion A,B,C, and D

EBM – Key Concepts Keep track of systematic reviews and randomized controlled trials with patient-oriented results Consider using synthesized database to keep up with literature Evaluate new information in context and for practice change

Diets/Supplements

Mediterranean diet What we know – Observational studies and a secondary prevention trial showed decrease cv risk Low fat diets standard treatment Takes extreme decrease in cholesterol intake to create plaque reversal Study for primary prevention vs low fat diet

Mediterranean diet 7447 people in Spain yrs old with type 2 DM or 3 risk factors followed for 4.8 yrs Mediterranean diet + olive oil or + nuts (mix of hazelnuts, almonds, and walnuts) Low fat diet Scores for diet adherence similar Combined endpoint of MI, stroke and death – both arms did better than low fat

Mediterranean diet But… all the benefit was in the prevention of ischemic strokes, and no sign women Reduction from 2.4% to 1.6% event rate Subgroups better if BMI > 30, nonsmokers, better adherence, htn, dyslipids, neg FH And the nuts or the olive oil was donated by food companies More intensive diet counseling control after 3 years

Omega-3 FA Supplements Omega-3 FA and fish oil What we know – recent studies indicating no benefit – cholesterol, dementia, The new Vit E – touted for everything but nothing panning out But wait…

Omega-3 FA Supplements Patients with RA < 12 mo, DMARD – naïve started on triple DMARD therapy 86 on high dose Fish oil supplement and 53 low dose fish oil supplement Previous meta analysis subj & obj benefits High dose fish oil group 22% less failure of triple therapy, remission 2x more in a year 88% f/u, only 122 pts finished, trend SAEs

Diagnostic studies

D-Dimer Very good at excluding DVT and PE if negative (<500) Not good in elderly ADJUST-PE study – JAMA March 19, 2014 Multicenter, consecutive ER patients Age-adjusted D-Dimer level (age x 10 mcg/dl) 3346 patients suspected PE (53-74)

D-Dimer age adjusted 19% PE rate High clinical likelihood – CTA 2898 – D-dimer, 337 in age-adjust 1 of 331 patients had confirmed VTE in 3 months Similar to rates with negative workup No CTA in negative group

Treatment Studies

Migraine Treatment Abortive therapy options – NSAIDS, Ergotamines, Triptans, Combo agents, Narcotics, Barbituates Significant risk of rebound headaches Patients often develop tolerance to meds Have to take meds right away to get benefit OTCs often used, most Rxs expensive

Migraine Treatment Cochrane Database Meta-analysis of 13 RCTs, noted in a PURL in The Journal of Family Practice, Feb aspirin tabs with/without 10 mg metoclopramide 5 placebo studies, 4 against common treatments, 4 both > 3200 patients, 2 hour pain-free, 2 hour headache relief, 24 hour headache relief

Migraine Treatment NNT vs placebo – 9 for pain free status Equivalent to sumatriptan 50 mg 2 hour measures 2/4 studies Metoclopramide reduced nausea and vomiting No GI bleeds, NNH 34 vs placebo for GI upset No comments about rebound headaches

Sore throat Cochrane systematic review 2012 Eight studies, 743 pts 369 kids, 374 adults Antibiotic with/without steroids Studies used one dose oral, three days oral, one dose IM and three days IM One day course oral probably enough – all were similar in effectiveness

Sore throat The Results: Reduced pain faster 8 vs 14 hours Mean time to resolution of pain 14 hours faster More pain resolved at 24 hours (27%) and 48 hours (30%) Not clear if would work without antibiotics No difference in risks, adverse events

Forearm fractures in kids UK study – 317 kids, mostly falls, mostly radius fractures, all minimally displaced Bone Joint Journal Dec 2013 Half fiberglass cast for 3 weeks (std care) Half soft cast tape for 3 weeks 2 patients had increased pain converted No complications at 6 mo f/u (91%)

Forearm fractures

Prevention news

TIAs/Minor Strokes What we know: Patients with TIAs and minor strokes at higher risk or another stroke (10-20% in 3 months) Clopidogrel + asa not better than either alone and increase risk of bleeding Asa benefits post TIA/stroke

TIAs/Minor Strokes Randomized, double-blind, in China 5170 patients with TIA/minor stroke All patients asa first day 75 – 300 mg Had to begin in study in first 24 hours Asa group 75 mg daily and placebo Clopidogrel group – 300 mg load, 75 mg daily + asa day 2-21, then placebo Only 90 day f/u

TIAs/Minor Strokes 8% strokes in 90 days in combined group, 11.7% in aspirin group, no sign difference in bleeding risks NNT 29, stroke rate in China 5x US Only included high risk TIAs – score based on age, blood pressure, clinical features, duration and diabetes Minor stroke < 4 stroke scale